Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 6NIH 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Autoimmune Diseases × 90 days × Clear all
NCT07039916 2026-05-22

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Immunovant Sciences GmbH

Phase 3 Recruiting
231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06359041 2026-05-18

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Cabaletta Bio

Phase 1/2 Active not recruiting
12 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡